A new drug to restore function following spinal cord injury.
Novoron Bioscience, Inc.
Novoron, a private biotechnology company, was founded in February 2013 to develop pharmaceutical therapies for nerve regeneration of the central nervous system (CNS). To date, we have received multiple Phase-1 grants from the National Institutes of Health (NIH) in order to pursue our passion: To further develop our ground-breaking discovery into therapies that promotes recovery for patients suffering from conditions related to a damaged CNS.
Our patent-protected discovery is a novel receptor on neurons that mediates the failure of nerves of the CNS to regenerate after damage. Pharmacologically blocking this receptor restores the natural regenerative capacity of neurons. We have, therefore, developed biologic agents capable of not only restoring neuronal growth, but also traversing the blood-brain barrier, a highly favorable pharmacological attribute for a CNS drug. In addition to the spinal cord injury (SCI) therapeutic we are currently developing, please read about our other initiatives.